Velcade

Velcade is a brand name of bortezomib, approved by the FDA in the following formulation(s):

VELCADE (bortezomib - injectable; intravenous, subcutaneous)

• 
  Manufacturer: MILLENNIUM PHARMS
  
  Approval date: May 13, 2003
  
  Strength(s): 3.5MG/VIAL ^[RLD]

Has a generic version of Velcade been approved?

No. There is currently no therapeutically equivalent version of Velcade available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Velcade. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Boronic ester and acid compounds
  Patent 5,780,454
  Issued: July 14, 1998
  Inventor(s): Adams; Julian & Ma; Yu-Ting & Stein; Ross & Baevsky; Matthew & Grenier; Louis & Plamondon; Louis
  Assignee(s): ProScript, Inc.
  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
  
  Patent expiration dates:
  
  
  • May 3, 2017
    
    ✓ 
    Drug product
  
  



• 
  Boronic ester and acid compounds, synthesis and uses
  Patent 6,083,903
  Issued: July 4, 2000
  Inventor(s): Adams; Julian & Ma; Yu-Ting & Stein; Ross & Baevsky; Matthew & Grenier; Louis & Plamondon; Louis
  Assignee(s): LeukoSite, Inc.
  Disclosed herein are boronic ester and acid compounds, their synthesis and uses. More specifically, disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
    ✓ 
    Patent use: TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
    ✓ 
    Drug product
  
  



• 
  Boronic ester and acid compounds, synthesis and uses
  Patent 6,297,217
  Issued: October 2, 2001
  Inventor(s): Adams; Julian & Ma; Yu-Ting & Stein; Ross & Baevsky; Matthew & Grenier; Louis & Plamondon; Louis
  Assignee(s): Millennium Pharmaceuticals, Inc.
  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
  
  
  
  • October 28, 2014
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
  
  
  
  • October 28, 2014
    
    ✓ 
    Patent use: TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
  
  



• 
  Boronic ester and acid compositions
  Patent 6,617,317
  Issued: September 9, 2003
  Inventor(s): Julian; Adams & Yu-Ting; Ma & Ross; Stein & Matthew; Baevsky & Louis; Grenier & Louis; Plamondon
  Assignee(s): Millennium Pharmaceuticals, Inc.
  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Formulation of boronic acid compounds
  Patent 6,713,446
  Issued: March 30, 2004
  Inventor(s): Shanker Lal; Gupta
  Assignee(s): The United States of America as represented by the Secretary of the Department of Health and Human Services
  The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
  
  Patent expiration dates:
  
  
  • January 25, 2022
    
    ✓ 
    Drug product
  
  



• 
  Boronic ester and acid compounds, synthesis and uses
  Patent 6,747,150
  Issued: June 8, 2004
  Inventor(s): Julian; Adams & Yu-Ting; Ma & Ross; Stein & Matthew; Baevsky & Louis; Grenier & Louis; Plamondon
  Assignee(s): Millennium Pharmaceuticals, Inc.
  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
    ✓ 
    Drug product
  
  



• 
  Formulation of boronic acid compounds
  Patent 6,958,319
  Issued: October 25, 2005
  Inventor(s): Gupta; Shanker Lal
  Assignee(s): The United States of America as represented by the Department of Health and Human Services
  The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
  
  Patent expiration dates:
  
  
  • January 25, 2022
    
    ✓ 
    Drug product
  
  



• 
  Boronic ester and acid compounds, synthesis and uses
  Patent 7,119,080
  Issued: October 10, 2006
  Inventor(s): Adams; Julian & Ma; Yu-Ting & Stein; Ross L. & Baevsky; Matthew & Grenier; Louis & Plamondon; Louis
  Assignee(s): Millennium Pharmaceuticals, Inc.
  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 20, 2011 - TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
  
  
  • March 25, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  
  • January 23, 2015 - NEW ROUTE
  
  

See also...

• Velcade Consumer Information (Drugs.com)
• Velcade Consumer Information (Wolters Kluwer)
• Velcade Consumer Information (Cerner Multum)
• Velcade Advanced Consumer Information (Micromedex)
• Velcade AHFS DI Monographs (ASHP)
• Bortezomib Consumer Information (Wolters Kluwer)
• Bortezomib Consumer Information (Cerner Multum)
• Bortezomib Intravenous Advanced Consumer Information (Micromedex)
• Bortezomib AHFS DI Monographs (ASHP)